Lung Cancer and COVID-19 in the Outpatient Setting: What Clinicians Need to Know
- CME / AMA PRA Category 1 Credit™
- MOC / ABIM MOC Part 2 Credit
- CNE / Nursing Contact Hours
- CPE / ACPE Contact Hours
PROGRAM OVERVIEW
Patients with underlying health conditions such as lung cancer are at greater risk for infection or complications from COVID-19. Because of this increased risk, it is important that these patients are carefully managed, with telemedicine replacing in-person visits where possible. However, monitoring patients via telemedicine requires special attention, particularly because symptoms of COVID-19 infection are similar to common adverse events associated with lung cancer treatment.
This activity, “Lung Cancer and COVID-19 in the Outpatient Setting: What Clinicians Need to Know” will provide clinicians with the most up-to-date guidance on managing lung cancer during the current pandemic, including information on the pathophysiology of Sars-Cov-2, the risk of infection in patients with lung cancer, and strategies to manage patient care and counsel through telemedicine.
AGENDA
Welcome and Introduction
Understanding the Pathophysiology of COVID-19
Recognizing the Risk of COVID-19 in Patients with Lung Cancer
Managing Patients with Lung Cancer During the COVID-19 Pandemic
Q&A Session and Concluding Remarks
TARGET AUDIENCE
This activity is intended for clinicians responsible for the daily management of patients with lung cancers.
EDUCATIONAL OBJECTIVES
This program is designed to address ACGME and NAM competencies, including delivering patient-centered care and practicing evidence-based medicine.
This program is designed to address ACPE competencies, including foundational knowledge and essentials for practice and care. At the conclusion of this education, participants should be able to:
- Discuss the most current understanding of the pathophysiology of COVID-19
- Recognize and evaluate factors that increase risk of COVID-19 among patients with lung cancer
- Integrate consensus recommendations for the safe and effective management of patients with lung cancer during the COVID-19 pandemic
- Provide counsel to patients with lung cancer regarding concerns or fears related to COVID-19
ACCREDITATION
Physicians – This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Boston University School of Medicine and Rockpointe. Boston University School of Medicine is accredited by the ACCME to provide continuing medical education for physicians
CREDIT DESIGNATION
Physicians – Boston University School of Medicine designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
For information about the accreditation of this program, please email: cme@bu.edu.
FACULTY

Associate Professor
University of Illinois at Chicago College of Pharmacy
Clinical Oncology Pharmacist, UI Health
Chicago, IL

Infectious Diseases Physician
Director of Antimicrobial Stewardship
Lahey Hospital and Medical Center
Assistant Professor of Medicine
Tufts University School of Medicine
Boston, MA

Division of Thoracic Oncology
European Institute of Oncology
Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS)
Milan, Italy

Nurse Practitioner
Abramson Cancer Center
University of Pennsylvania
Philadelphia, PA
ABIM MOC DESIGNATION STATEMENT
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
For ABIM MOC points, your information will be shared with the ABIM through Boston University's ACCME Program and Activity Reporting System (PARS). Please allow 6-8 weeks for your MOC points to appear on your ABIM records.
PHARMACIST ACCREDITATION STATEMENT
The Potomac Center for Medical Education is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
PHARMACIST CREDIT DESIGNATION STATEMENT
This is a knowledge-based activity.
For information about this continuing pharmacy education (CPE) activity, please email: contact@potomacme.org.
NURSING CREDIT STATEMENT
DISCLOSURES OF CONFLICTS OF INTEREST
Boston University School of Medicine asks all individuals, and their spouses/partners, involved in the development and presentation of Continuing Medical Education (CME) and Continuing Nursing Education (CNE) activities to disclose all relevant financial relationships with commercial interests. This information is disclosed to CME activity participants prior to the start of the educational activity. Boston University School of Medicine has procedures to resolve all conflicts of interest. In addition, faculty members are asked to disclose when any unapproved use of pharmaceuticals and devices is being discussed.
Faculty and Steering Committee Disclosures
The faculty and steering committee reported the following relevant financial relationships that they or their spouse/partner have with commercial interests:
Sandra Cuellar, PharmD, BCOP: Nothing to disclose
J. Morgan Freiman, MD, MSc: Nothing to disclose
Antonio Passaro, MD, PhD: Consultant: Agilent, AstraZeneca, Bristol Myers Squibb, Lilly, Merck Sharp & Dohme, Pfizer, Roche
Beth Sandy, MSN, CRNP: Speaker's Bureau: AstraZeneca, Merck, Takeda
Umit Tapan, MD, BUSM CME Course Director: Nothing to disclose
Planners and Managers
The planners and mangers reported the following relevant financial relationships that they or their spouse/partner have with commercial interests:
Chelsey Goins, PhD; Elizabeth Drury; Natalie Sanfratello, MPH: Nothing to disclose.
Content Reviewers
The content reviewers reported the following relevant financial relationships that they or their spouse/partner have with commercial interests:
Katie Propst, PhD: Nothing to disclose.
DISCLAIMER
FDA DISCLOSURE
SYSTEM REQUIREMENTS
INSTRUCTIONS FOR PARTICIPANTS AND OBTAINING CME/CE CREDIT AND MOC POINTS
PROVIDER
Jointly provided by Boston University School of Medicine, Potomac Center for Medical Education, and Rockpointe
In collaboration with the American Lung Association
Click here for the Rockpointe Privacy Policy
SUPPORTER
This program is supported by an educational grant from Daiichi Sankyo, Inc.
RELATED COURSES
Obesity and COVID-19 in the Outpatient Setting: What Clinicians Need to Know
Credits 1.00 (60 min)
Format Webinar
Hardened Hope: Care Advances for Patients with Fibrodysplasia Ossificans Progressiva
Credits 1.00 (60 min)
Format Webinar

Oct